Immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 antibodies, are widely used in the treatment of various cancer types, including renal cell carcinoma (RCC) [1,2]. This evidence concerns the gene CD274 and renal cell carcinoma.